Skip to main content

Table 3 Efficacy analysis

From: A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC

 

N = 68(%)

CR

0(0)

PR

7(10.3)

SD

47(69.1)

ORR

7(10.3)

DCR

54(79.4)

  1. Abbreviations: CR complete response, PR partial response, SD stable disease, ORR objective response rate, DCR disease control rate
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us